aranesp 130mcg/0,65ml pf.syr inj.sol
amgen europe bv, breda, holland - darbepoetin alfa - ΕΝΕΣΙΜΟ ΔΙΑΛΥΜΑ - 130mcg/0,65ml pf.syr - ΒΙΟΛΟΓΙΚΟ ΠΡΟΙΟΝ (ΒΠ)
aranesp 130mcg/0,65ml pf.pen (sureclick) inj.sol
amgen europe bv, breda, holland - darbepoetin alfa - ΕΝΕΣΙΜΟ ΔΙΑΛΥΜΑ - 130mcg/0,65ml pf.pen (sureclick) - ΒΙΟΛΟΓΙΚΟ ΠΡΟΙΟΝ (ΒΠ)
aranesp 25mcg/1mlvial inj.sol
amgen europe bv, breda, holland - darbepoetin alfa - ΕΝΕΣΙΜΟ ΔΙΑΛΥΜΑ - 25mcg/1mlvial - ΒΙΟΛΟΓΙΚΟ ΠΡΟΙΟΝ (ΒΠ)
aranesp 40mcg/1mlvial inj.sol
amgen europe bv, breda, holland - darbepoetin alfa - ΕΝΕΣΙΜΟ ΔΙΑΛΥΜΑ - 40mcg/1mlvial - ΒΙΟΛΟΓΙΚΟ ΠΡΟΙΟΝ (ΒΠ)
aranesp 60mcg/1mlvial inj.sol
amgen europe bv, breda, holland - darbepoetin alfa - ΕΝΕΣΙΜΟ ΔΙΑΛΥΜΑ - 60mcg/1mlvial - ΒΙΟΛΟΓΙΚΟ ΠΡΟΙΟΝ (ΒΠ)
aranesp 100mcg/1mlvial inj.sol
amgen europe bv, breda, holland - darbepoetin alfa - ΕΝΕΣΙΜΟ ΔΙΑΛΥΜΑ - 100mcg/1mlvial - ΒΙΟΛΟΓΙΚΟ ΠΡΟΙΟΝ (ΒΠ)
aranesp 200mcg/1mlvial inj.sol
amgen europe bv, breda, holland - darbepoetin alfa - ΕΝΕΣΙΜΟ ΔΙΑΛΥΜΑ - 200mcg/1mlvial - ΒΙΟΛΟΓΙΚΟ ΠΡΟΙΟΝ (ΒΠ)
aranesp 300mcg/1mlvial inj.sol
amgen europe bv, breda, holland - darbepoetin alfa - ΕΝΕΣΙΜΟ ΔΙΑΛΥΜΑ - 300mcg/1mlvial - ΒΙΟΛΟΓΙΚΟ ΠΡΟΙΟΝ (ΒΠ)
mircera
roche registration gmbh - methoxy polyethylene glycol-epoetin beta - anemia; kidney failure, chronic - Αντινεμμικά παρασκευάσματα - treatment of symptomatic anaemia associated with chronic kidney disease (ckd) in adult patients (see section 5. treatment of symptomatic anaemia associated with chronic kidney disease (ckd) in paediatric patients from 3 months to less than 18 years of age who are converting from another erythropoiesis stimulating agent (esa) after their haemoglobin level was stabilised with the previous esa (see section 5.
omnipaque 51.8% (24)% inj.sol
schepa o.e. ΠΑΝΑΓΑΚΗΣ Γ. & ΣΙΑ - iohexol - ΕΝΕΣΙΜΟ ΔΙΑΛΥΜΑ - 51.8% (24)% - ΣΚΙΑΓΡΑΦΙΚΟ